Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.28 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: antrafenine | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 8 Parkinson's papers of 308 | 0.71 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 1391
Sealed predictions
- PTGDS in dopamine neurons, braak-0.24 (p 0.529) → +0.17 (p 0.670)receipt 1398
Swarm cases
receipt 1398: PTGDS in dopamine neurons, braak
- power
- full sample +0.08 (p 0.754, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.11 (p 0.664, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.18 (p 0.465, n 18). could be the mix.
- skeptic
- leave-one-out range -0.03 to +0.21, sign flips 4; without severely affected donors +0.08 (p 0.754, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PTGDS in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts